Data_Sheet_2_miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells.PDF

Cisplatin resistance is a major cause of treatment failure in advanced ovarian cancer. The limited evidence shows the paradoxical regulation of miR-205 on chemotherapy resistance in cancer. Herein, we found that miR-205-5p was enormously increased in cisplatin-resistant C13K ovarian cancer cells compared with its cisplatin-sensitive OV2008 parental cells using miRNA microarrays, which was further verified by quantitative PCR. Furthermore, we confirmed that inhibition of miR-205-5p upregulated PTEN and subsequently attenuated its downstream target p-AKT, which inversed C13K cells from cisplatin resistance to sensitivity. Our data suggest that miR-205-5p contributes to cisplatin resistance in C13K ovarian cancer cells may via targeting PTEN/AKT pathway.

顺铂耐药是晚期卵巢癌治疗失败的主要诱因。现有有限证据表明，微小RNA-205（miR-205）对癌症化疗耐药的调控存在悖论性作用。本研究通过miRNA微阵列分析发现，相较于顺铂敏感的亲本细胞OV2008，顺铂耐药卵巢癌细胞C13K中miR-205-5p的表达水平显著升高，该结果经定量聚合酶链式反应（quantitative PCR）进一步验证。进一步研究证实，抑制miR-205-5p可上调PTEN的表达，继而减弱其下游靶蛋白p-AKT的活性，使C13K细胞从顺铂耐药表型逆转为顺铂敏感表型。本研究数据表明，miR-205-5p可能通过靶向调控PTEN/AKT信号通路，参与介导C13K卵巢癌细胞的顺铂耐药过程。